Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu 44600, Nepal.
Tribhuvan University Teaching Hospital, Maharajgunj, Kathmandu 44600, Nepal.
J Interv Cardiol. 2022 Aug 21;2022:1816504. doi: 10.1155/2022/1816504. eCollection 2022.
The electronic databases PubMed, medRxiv, ScienceDirect, and Google Scholar were searched for relevant literature from inception to the 10 of December, 2021. Thus, retrieved literature was screened by title and abstract, followed by full-text screening based on the eligibility criteria. The risk of bias was accessed using the quality in prognostic studies (QUIPSs) tool. The data on cardiovascular outcomes about CT-IGFBP-4 levels were studied and the results were synthesized.
Five studies with a total of 1,417 participants were included in our study. The studies reported a low risk of bias. The mean age of the participants was 66.14 and more than 65% were males. Elevated CT-IGFBP-4 levels were associated with poor cardiovascular outcomes and increased mortality in severely ill patients. In contrast, there were no significant findings in the case of stable patients. Sandwich ELISA using lithium-heparin plasma provided a better detection limit of 0.15 ng/ml, low cross-reactivity (<2%), and generated linear results between 12 and 500 ng/ml.
CT-IGFBP-4 is an efficient biomarker for the prediction of MACE and mortality in patients with severe ischemic cardiovascular events.
从建库至 2021 年 12 月 10 日，我们在电子数据库 PubMed、medRxiv、ScienceDirect 和 Google Scholar 中搜索相关文献。通过标题和摘要筛选检索到的文献，然后根据纳入标准进行全文筛选。使用预后研究质量工具（QUIPSs）评估偏倚风险。研究 CT-IGFBP-4 水平与心血管结局相关的数据，并对结果进行综合分析。
我们的研究纳入了 5 项共 1417 名参与者的研究。这些研究报告的偏倚风险较低。参与者的平均年龄为 66.14 岁，超过 65%为男性。CT-IGFBP-4 水平升高与重症患者不良心血管结局和死亡率增加相关。相比之下，稳定患者的结果没有显著差异。使用锂肝素血浆的夹心 ELISA 法提供了更好的检测限（0.15ng/ml）、低交叉反应性（<2%），并在 12 至 500ng/ml 之间产生线性结果。
CT-IGFBP-4 是预测严重缺血性心血管事件患者 MACE 和死亡率的有效生物标志物。
